Compare Hershey Co (HSY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Summit Therapeutics Inc — how do they compare? Hershey Co trades at $162.36 (market cap $32.66B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Hershey Co is far larger — about 2.4× Summit Therapeutics Inc's market cap, and Hershey Co pays a 3.57% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Summit Therapeutics Inc for 16 Days on average.
| HSY | SMMT | |
|---|---|---|
Market Cap | $32.66B | $13.71B |
Volume | 1,578,237 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $26.38 |
52-Week Low | $157.61 | $12.43 |
Typical Hold Time | 135 Days | 16 Days |
Enterprise Value | $37.79B | $13.04B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $162.74, up 1.5% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats (3 of last 4 quarters) with Q3 2026 results pending. Revenue grew to $11.69B in 2025, though net margin compressed to 7.55% from 19.82% in 2024. Analyst consensus targets $204.62 (25.7% upside) with 65.7% hold ratings. Recent news highlights dividend resumption and international leadership changes.
HSY presents a mixed outlook: valuation appears reasonable (P/E 22.2) with strong brand positioning, but faces margin pressure from commodity costs. The technical bearish trend near key support at $161 suggests near-term caution. Long-term investors may find value given dividend growth resumption and consistent market share, though cocoa price volatility remains a key risk.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
